SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing . Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Novartis can't make enough of it, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Alex Denner secures victory in Amarin vote, ousting chair and adding supporters to board, Whos charting paths for LGBTQ+ leaders in biopharma? Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. The resulting proteome diversification is a fundamental physiological aspect of tissue fate and function. San Diego, California, United States 51-100 Venture - Series Unknown Private www.biosplice.com 5,337 Highlights Total Funding Amount $778M Contacts 69 Employee Profiles 7 Investors 11 Similar Companies 14 Find More Contacts for Biosplice Therapeutics Biosplice Therapeutics (Excluding its subsidiaries) has filed 96 patent applications at USPTO so far (Excluding Design and PCT applications). The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer. All rights reserved. EquityZen helps investors to access private companies and their employees to sell shares. Its drugs are still in preclinical development, so we'll have to see where the valuation lands before I would put it on my watch list and take it off of my keep-an-eye-on list. Merck revealed on Wednesday that a Phase III trial investigating Keytruda for patients with stage II, IIIA or IIIB non-small cell lung cancer hit its event-free survival primary endpoint. Biosplice Therapeutics was founded in 2021. The Motley Fool owns shares of and recommends Bristol Myers Squibb. 2/27/2023. Each of these companies announced their intentions this week. His research on drug delivery, which led him to co-found Moderna in 2010, went on to prove critical in developing the companys Covid-19 vaccine. Other biopharma companies will soon make their debut on stock exchanges. The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. If you're already an Endpoints subscriber, enter your email below for a Systems Engineer. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200, GLOBAL MARKETS-US stocks muted, Treasuries dip as inflation worries linger, Stock market news today: Stocks waver after key manufacturing data, Salesforce set to report earnings Thursday, Goldman Sachs tries to reset firm culture after three 'unusual' years, Shipping companies reach $97M California oil spill agreement. At least those big pharma partners have looked at the early-stage preclinical data. The stick will trade under the ticker symbol IKNA.. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. Funds from the IPO and the Series B will support development of the companys oncology pipeline. Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. 1985 - 2023 BioSpace.com. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Copyright 2023 Forge Global, Inc. All rights reserved. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease,CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Notable lists of unicorn companies are maintained by The Wall Street Journal, Fortune Magazine, CNNMoney/CB Insights, TechCrunch, PitchBook/Morningstar, and Tech in Asia. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Nominate them for Endpoints annual report, Keytruda hits one primary endpoint for use before and after surgery in lung cancer. The name Biosplice echoes our science much more than Samumed does.. Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. It might be worth that much, but on a risk-adjusted basis, I just don't know. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. Out of these 85 have been granted leading to a grant rate of 98.8%.
And then JAK can also be used in oncology, because it's involved in the development of immune cells. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling.
They have two partners at Bristol Myers Squibb (BMY 0.83%) and Roche [Holding] (RHHBY 0.22%). Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. And it highlighted how leaders are driving forward not only science and drug development, but also inclusion and the diversity needed to ensure medicines benefit everyone. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. Alfredo Naj Domingos prostate cancer was spreading. Funds from that round, as well as the IPO, will be used to advance the companys muscular dystrophy program, as well as other indications. Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Below are the key stats of Biosplice Therapeutics patent prosecution at the USPTO. Just weeks after activist investor Alex Denner called for Amarins chairman to step down, the Irish biotechs shareholders have voted in Denners favor. Keith Speights owns shares of Bristol Myers Squibb. Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. This morning, two of those companies, Ikena Oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the exchange. They say they will not only cure arthritis, but also cancer in the future with their amazing technology. Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug. Biosplice Therapeutics is developing tissue-level regeneration technologies that will be used in the fields of functional medicine and regenerative medicine. Now, the biotech is laying off a large swath of its staff as it undergoes a pipeline overhaul. Biosplices target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular command and control center. Active, Closed, Last funding round type (e.g. Brief Summary: This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. View contacts for Biosplice Therapeutics to access new leads and connect with decision-makers. Log in. Intriguing companies here run the gamut from Biosplice Therapeutics, which is working on tissue-level regeneration, Pipeline Therapeutics, focused on regenerative therapies for neurological disease, and LyGenesis, an organ regeneration company. Funding Rounds Number of Funding Rounds 5 Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. About. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. Buy or sell Biosplice Therapeutics stock Learn more about Biosplice Therapeutics IPO Register for Details Chief Operating Officer. EquityZen Securities LLC (EquityZen Securities) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. Biosplice's mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. Biosplice Therapeutics is a private company and not publicly traded. Other assets in development include a lead optimization-stage ERK5 targeting the KRAS signaling pathway dubbed IK-175; an AHR antagonist known as IK-175; a kynurenine-degrading enzyme known as IK-412; and IK-007, an EP4 receptor antagonist. But there was a new treatment he could try: a targeted radiotherapy called Pluvicto if he could get it in time. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need., Joy Ghosh, PhD, of Eventide Asset Management, added, Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1 With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. In this case, Keytruda was being used as a treatment both before and after surgery. Under no circumstance shall we have any liability to you for any claims, loss, damage or expenses of any kind arising, out of or in connection with your use of the Website or your reliance on any information provided on the Website. Stemming from foundational discoveries in Wnt pathway. Published: Mar 26, 2021
When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data Vividion Therapeutics has filed to go public. After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. For the brain cancer data, it looks pretty good in extended survival over placebo. Cost basis and return based on previous market day close. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Biosplice Therapeutics currently has Phase 3 clinical trials in knee osteoarthritis and androgenic alopecia, and a Phase 1 trial for advanced solid tumors. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the command and control center of proteome diversification.